Date published: 2026-7-9

1-800-457-3801

SCBT Portrait Logo
Seach Input

SHISA2 CRISPR/Cas9 KO Plasmid (m): sc-432346

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: mouse
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • SHISA2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SHISA2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    SHISA2 CRISPR/Cas9 KO Plasmid (m)

    sc-432346
    20 µg
    $397.00

    Overview

    Shisa2 encodes SHISA2, a single-pass transmembrane protein in the Shisa family that can modulate trafficking and maturation of cell-surface receptors, thereby influencing receptor availability and downstream signaling. In mouse cells, SHISA2 has been linked to regulation of developmental and differentiation programs, with reported roles in controlling WNT and FGF pathway responsiveness through effects on receptor processing. By tuning receptor-mediated signaling intensity, SHISA2 may impact epithelial–mesenchymal transitions, tissue morphogenesis, and cell state stability. Dysregulated SHISA2 expression or function has been associated in the literature with altered growth-factor signaling networks relevant to cancer biology and other disorders characterized by aberrant differentiation and signaling rewiring.

    SHISA2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Shisa2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Shisa2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Shisa2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SHISA2 protein expression.

    This CRISPR knockout system enables efficient generation of Shisa2-deficient cell models for investigation of SHISA2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting Shisa2 exon(s) critical for SHISA2 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple Shisa2 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by SHISA2 CRISPR/Cas9 KO Plasmid (m) and SHISA2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Shisa2 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by SHISA2 HDR Plasmid (m) and SHISA2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Shisa2 homology arms to support homology-directed repair at defined Shisa2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.